Acute attacks of hereditary angioedema (DBCOND0024027)
Identifiers
- Synonyms
- Acute attacks Hereditary angioedema / Hereditary angioedema attack / Acute attack of hereditary angioedema / Hereditary angioedema C1 inhibitor deficiency / Hereditary angioedema / Hereditary angioneurotic edema (disorder) / Angioedemas, Hereditary / C1 esterase inhibitor deficiency
Associated Data
- Indicated Drugs and Targets
Drug Description Targets Berotralstat An inhibitor of plasma kallikrein used for prophylaxis of angioedema attacks in patients with hereditary angioedema.- Cytochrome P450 2D6enzyme
- Cytochrome P450 3A4enzyme
- ATP-dependent translocase ABCB1transporter
- Broad substrate specificity ATP-binding cassette transporter ABCG2transporter
- Plasma kallikreintarget
Conestat alfa A recombinant C1INH used for the treatment of acute attacks of hereditary angioedema (HAE) due to C1 esterase inhibitor deficiency in adults.- Complement C1r subcomponenttarget
- Complement C1s subcomponenttarget
- Plasma kallikreintarget
- Coagulation factor XIItarget
- Prothrombintarget
- Coagulation factor XItarget
- Tissue-type plasminogen activatortarget
Ecallantide A kallikrein inhibitor used to prevent and treat acute attacks caused by Hereditary Angioedema (HAE).- Plasma kallikreintarget
Human C1-esterase inhibitor A C1 inhibitor used to prevent angioedema attacks associated with hereditary angioedema.- Complement C1r subcomponenttarget
- Complement C1s subcomponenttarget
- Plasma kallikreintarget
- Coagulation factor XIItarget
- Prothrombintarget
- Coagulation factor XItarget
- Tissue-type plasminogen activatortarget
Icatibant A bradykinin B2 receptor antagonist used to treat acute episodes of swelling and inflammation associated with hereditary angioedema (HAE).- B2 bradykinin receptortarget
- Aminopeptidase Ntarget
Lanadelumab A monoclonal antibody targeted against kallikrein which is used to treat attacks of hereditary angioedema.- Plasma kallikreintarget
- Clinical Trials
Identifier Title Drug(s) Purpose Phase Status NCT06343779 Study of Oral Deucrictibant Soft Capsule for On-Demand Treatment of Angioedema Attacks in Adolescents and Adults With Hereditary Angioedema No drug interventions treatment 3 recruiting NCT05396105 Extension Study of Oral PHA-022121 for Acute Treatment of Angioedema Attacks in Patients with Hereditary Angioedema treatment 2 / 3 enrolling_by_invitation NCT05047185 Dose-ranging Study of Oral PHA-022121 for Prophylaxis Against Angioedema Attacks in Patients With Hereditary Angioedema Type I or Type II prevention 2 active_not_recruiting NCT04618211 Dose-ranging Study of Oral PHA-022121 for Acute Treatment of Angioedema Attacks in Patients With Hereditary Angioedema treatment 2 completed